Download PDF
Semin Respir Crit Care Med 2004; 25(3): 283-295
DOI: 10.1055/s-2004-829501
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Mycobacterial Infections Caused by Nontuberculous Mycobacteria

Leonid Heifets1 , 2
  • 1National Jewish Medical and Research Center, Denver, Colorado
  • 2Colorado University Health Sciences Center, Denver, Colorado
Further Information

Publication History

Publication Date:
29 June 2004 (online)

    Permissions and Reprints

The purpose of this review is to familiarize a broad range of medical professionals with a relatively new and growing problem of infections caused by mycobacteria other than M. tuberculosis and M. leprae. There are at least 60 mycobacterial species that have been identified as causative agents of diseases in humans. They are all environmental bacteria, and they are not transmitted from person to person. The usual source of infection is water, soil, and aerosols developed from these sources. The probability of contracting such a disease depends not only on the closeness of interaction with an environment containing an enhanced concentration of bacteria but also and foremost on the sensitivity of an individual to these infections, which may depend on the state of immunity and other so-called predisposing conditions. Therefore, these infections are often referred to as opportunistic, and the group of organisms causing them are usually referred to as nontuberculous mycobacteria (NTM). This review addresses in a condensed form various aspects of these infections, including bacteriology, clinical manifestations, diagnosis, and therapy. The reader will be able to find more details on each of these topics in several reviews and some original papers cited in this article.

KEYWORDS

Mycobacterium - nontuberculous mycobacteria (NTM) - environmental mycobacteria - infections with opportunistic mycobacteria

REFERENCES

  • 1 Amfah G, Bonsu F, Tetteh C et al.. Buruli ulcer in Ghana: results of a national case search.  Emerg Infect Dis. 2002;  8 167-170
    PubMedGoogle Scholar
  • 2 Van der Wert T, Stinear T, Stienstra Y, Van der Graaf W TA, Small P L. Mycobactones and Mycobacterium ulcerans disease.  Lancet. 2003;  362 1062-1064
    CrossrefPubMedGoogle Scholar
  • 3 Wolinsky E. Nontuberculous mycobacteria and associated diseases.  Am Rev Respir Dis. 1979;  119 107-159
    PubMedGoogle Scholar
  • 4 Wayne L G, Sramek H A. Agents of newly recognized or infrequently encountered mycobacterial diseases.  Clin Microbiol Rev. 1992;  5 1-25
    PubMedGoogle Scholar
  • 5 Goodfellow M, Wayne L G. Taxonomy and nomenclature. In: Ratledge C, Stanford J The Biology of the Mycobacteria, Vol 1. London; Academic 1982: 471-521
    Google Scholar
  • 6 Woods G L, Washington J A. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects.  Rev Infect Dis. 1987;  9 275-294
    PubMedGoogle Scholar
  • 7 Goodfellow M, Magee J G. Taxonomy of mycobacteria. In: Gangadharam PRJ, Jenkins PA Mycobacteria, Vol. I: Basic Aspects. New York; Chapman and Hall (International Thomson Publishing) 1998: 1-71
    Google Scholar
  • 8 Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of 1990s.  Clin Microbiol Rev. 2003;  16 319-354
    CrossrefPubMedGoogle Scholar
  • 9 Sneath P HA. International Code of Nomenclature of Bacteria. Washington DC; American Society for Microbiology 1992
    Google Scholar
  • 10 Wallace R J, Glassroth J, Griffith D E, Oliver K N, Cook J L, Gordin F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria (American Thoracic Society Statement).  Am J Respir Crit Care Med. 1997;  156 1-25
    PubMedGoogle Scholar
  • 11 Good R C, Snider D E. Isolation of nontuberculous mycobacteria in the United States.  J Infect Dis. 1982;  146 829-833
    CrossrefPubMedGoogle Scholar
  • 12 Kent P T, Kubica G P. Public Health Mycobacteriology (a guide for the level III laboratory). Atlanta; Centers for Disease Control 1985
    Google Scholar
  • 13 Witebsky F G, Kruczak-Filipov P. Identification of mycobacteria by conventional methods. In: Heifets LB Clinical Mycobacteriology. Philadelphia; WB Saunders 1996: 569-602 Clinics in Laboratory Medicine, Vol 16
    Google Scholar
  • 14 Heifets L B, Jenkins P A. Speciation of mycobacteria in clinical laboratories. In: Gangadharam PRJ, Jenkins PA Mycobacteria, Vol. I: Basic Aspects. New York; Chapman and Hall (International Thompson Publishing) 1998: 308-350
    Google Scholar
  • 15 Rogall T, Flohr T, Böttger E C. Differentiation of Mycobacterium species by direct sequencing of amplified DNA.  J Gen Microbiol. 1990;  136 1915-1920
    PubMedGoogle Scholar
  • 16 Butler W R, Jost K C, Kilburn J O. Identification of mycobacteria by high-performance liquid chromatography.  J Clin Microbiol. 1991;  29 2468-2472
    PubMedGoogle Scholar
  • 17 Kirschner P, Springer B, Vogel U. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a two year experience in a clinical laboratory.  J Clin Microbiol. 1993;  31 2882-2889
    PubMedGoogle Scholar
  • 18 Thibert L, Lapierre S. Routine application of high-performance liquid chromatography for identification of mycobacteria.  J Clin Microbiol. 1993;  31 1759-1763
    PubMedGoogle Scholar
  • 19 Glickman S E, Kilburn S O, Butler W R. Rapid identification of mycolic acid patterns of mycobacteria by high-performance liquid chromatography using pattern recognition software and a Mycobacterium library.  J Clin Microbiol. 1994;  32 740-749
    PubMedGoogle Scholar
  • 20 Roberts G D, Böttger E C, Stockman L. Methods for the rapid identification of mycobacterial species. In: Heifets LB Clinical Mycobacteriology. Philadelphia; WB Saunders 1996: 603-639 Clinics in Laboratory Medicine, Vol 16
    Google Scholar
  • 21 El Amin N M, Hanson H S, Pettersson B, Petrini B, Von Stedink L V. Identification of nontuberculous mycobacteria: 16S rRNA gene sequense analysis vs. conventional methods.  Scand J Infect Dis. 2000;  32 47-50
    PubMedGoogle Scholar
  • 22 Butler W R, Guthertz L S. Mycolic acid analysis by high-performance liquid chromatography for identification of Mycobacterium species.  Clin Microbiol Rev. 2001;  14 704-726
    CrossrefPubMedGoogle Scholar
  • 23 Claud J L, Neal J, Rosenberry R et al.. Identification of Mycobacterium spp. by using a commercial 16S ribosomal DNA sequencing kit and additional sequencing libraries.  J Clin Microbiol. 2002;  40 400-406
    CrossrefPubMedGoogle Scholar
  • 24 Hall L, Doerr K A, Wohlfiel S L, Roberts G D. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribisomal DNA sequencing and its integration into routine clinical mycobacteriology laboratory.  J Clin Microbiol. 2003;  41 1447-1453
    CrossrefPubMedGoogle Scholar
  • 25 Eisenach K D, Sifford M D, Cave M D, Bates J H, Crawford J T. Detection of Mycobacterium tuberculosis in sputum samples using polymerase chain reaction.  Am Rev Respir Dis. 1991;  144 1160-1163
    PubMedGoogle Scholar
  • 26 Forbes B A, Hicks K ES. Direct detection of Mycobacterium tuberculosis in respiratory specimens in a clinical laboratory by polymerase chain reaction.  J Clin Microbiol. 1993;  31 1688-1694
    PubMedGoogle Scholar
  • 27 Shinnick T M, Jonas V. Molecular approach to the diagnosis of tuberculosis. In: Bloom BR Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC; ASM 1994: 517-530
    Google Scholar
  • 28 Pfyffer G E, Kissling P, Wirth R, Weber R. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system.  J Clin Microbiol. 1994;  32 918-923
    PubMedGoogle Scholar
  • 29 Desmond E, Loretz K. Use of the Gen-Probe amplified Mycobacterium Tuberculosis Direct Test for early detection of Mycobacterium tuberculosis in BACTEC 12B medium.  J Clin Microbiol. 2001;  39 1993-1995
    CrossrefPubMedGoogle Scholar
  • 30 Jost Jr K C, Dunbar D F, Barth S S, Headley V L, Elliot L B. Identification of Mycobacterium tuberculosis and M. avium complex directly from smear-positive sputum specimens and Bactec 12B cultures by high-performance liquid chromatography with fluorescence detection and computer-driven pattern recognition models.  J Clin Microbiol. 1995;  33 1270-1277
    PubMedGoogle Scholar
  • 31 Wolinsky E, Rynearson T K. Mycobacteria in soil and their relation to disease-associated strains.  Am Rev Respir Dis. 1968;  97 1031-1037
    PubMedGoogle Scholar
  • 32 Portaels F. Epidemiology of mycobacterial diseases.  Clin Dermatol. 1995;  13 297 207-222
    CrossrefPubMedGoogle Scholar
  • 33 Falkinham J O. Epidemiology of infection by nontuberculous mycobacteria.  Clin Microbiol Rev. 1996;  9 177-215
    CrossrefPubMedGoogle Scholar
  • 34 Falkinham J O. Nontuberculous mycobacteria in the environment. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 520-553 Clinics in Chest Medicine, Vol 23
    Google Scholar
  • 35 Marras T K, Daley C L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterisl Infections. Philadelphia; WB Saunders 2003: 553-568 Clinics in Chest Medicine, Vol 23
    Google Scholar
  • 36 Iseman M D, Buschman D L, Ackerson L M. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by M. avium complex.  Am Rev Respir Dis. 1991;  144 914-916
    CrossrefPubMedGoogle Scholar
  • 37 Iseman M D. Mycobacterium avium complex and the normal host: the other side of the coin.  N Engl J Med. 1989;  321 896-898
    PubMedGoogle Scholar
  • 38 Prince D S, Peterson D D, Steiner R M et al.. Infection with Mycobacterium avium complex in patients without predisposing conditions.  N Engl J Med. 1989;  321 863-868
    CrossrefPubMedGoogle Scholar
  • 39 Reich J M, Johnson R E. Mycobacterium avium complex pulmonary disease: incidence, presentation, and response to therapy in a community setting.  Am Rev Respir Dis. 1991;  143 1381-1385
    PubMedGoogle Scholar
  • 40 Kubo K, Yamazaki Y, Haciya T et al.. Pulmonary M. avium-intracellulare infection in patient without known predisposing lung disease.  Lung. 1998;  176 381-389
    PubMedGoogle Scholar
  • 41 Hawkins C C, Gold W M, Whimbey E et al.. M. avium complex infections in patients with aquired immunodeficiency syndrome.  Ann Intern Med. 1986;  105 184-188
    PubMedGoogle Scholar
  • 42 Nightingale S D, Byrd L T, Southern P M, Jockusch J D, Cal S X, Wynne B A. Incidence of M. avium-intracellulare complex in human immunodeficiency virus-positive patients.  J Infect Dis. 1992;  165 1082-1085
    CrossrefPubMedGoogle Scholar
  • 43 Horsburgh C R. M. avium complex infection in the aquired immunodeficiency syndrome.  N Engl J Med. 1991;  324 1332-1338
    PubMedGoogle Scholar
  • 44 Sanchez T, Vanderkolk J, Seay S, Heifets L. Quantitation of mycobacteria in blood specimens from patients with AIDS.  Tubercle and Lung Disease. 1994;  75 386-390
    CrossrefPubMedGoogle Scholar
  • 45 Heifets L B. Quantitative cultures and drug susceptibility testing of M. avium clinical isolates before and during the antimicrobial therapy (review).  Res Microbiol. 1994;  145 188-196
    CrossrefPubMedGoogle Scholar
  • 46 Jones D, Havlir D V. Nontuberculouse mycobacteria in HIV infected patient. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 665-674 Clinics in Chest Medicine, Vol 23
    Google Scholar
  • 47 Yates M D, Grange J M, Collins C H. The nature of mycobacterial disease in south-east England.  J Epidemiol. 1986;  40 295-300
    PubMedGoogle Scholar
  • 48 Bittner M J, Horowitz E A, Safranek T J, Preheim L C. Emergence of M. kansasii as a leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital.  Clin Infect Dis. 1996;  22 1109-1110
    PubMedGoogle Scholar
  • 49 Griffith D E. Management of disease due to M. kansasii . In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 613-625 Clinics in Chest Medicine, Vol 23
    Google Scholar
  • 50 Byrd R P, Mirza S, Roy T M. Lady Windermere's syndrome: an atypical presentation of an atypical mycobacterium.  J Tenn Med Assoc. 1995;  88 303-305
    PubMedGoogle Scholar
  • 51 Dhillon S S, Watanakunakorn C. Lady Windermere Syndrome: middle lobe bronchiectasis and M.avium complex infection due to voluntary cough suppression.  Clin Infect Dis. 2000;  30 572-575
    CrossrefPubMedGoogle Scholar
  • 52 Levin D L. Radiology of pulmonary M. avium-intracellulare complex. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 603-612 Clinics in Chest Medicine, Vol 23
    Google Scholar
  • 53 Griffith D E, Girard W M, Wallace R J. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an anlysis of 154 patiemts.  Am Rev Respir Dis. 1993;  147 1271-1278
    CrossrefPubMedGoogle Scholar
  • 54 Daley C L, Griffith D E. Pulmonary disease caused by rapidly growing mycobacteria. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 623-632 Clinics in Chest Medicine, Vol 23
    Google Scholar
  • 55 Johnston J M. Izumi AK Cutaneous M. marinum infection (“swimming pool granuloma”).  Clin Dermatol. 1988;  5 68-75
    PubMedGoogle Scholar
  • 56 Males B M, West T E, Bartolomew W R. M. haemophilum infection in a patient with aquired immunodeficiency syndrome.  J Clin Microbiol. 1987;  25 186-190
    PubMedGoogle Scholar
  • 57 Rogers P L, Walker R E, Lane H C et al.. Disseminated M. haemophilum infection in two patients with the aquired immunodeficiency syndrome.  Am J Med. 1988;  84 640-642
    CrossrefPubMedGoogle Scholar
  • 58 Wallace R J. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria M. fortuitum and M. chelonae .  Clin Chest Med. 1989;  10 419-429
    PubMedGoogle Scholar
  • 59 Dautzenberg B, Truffot C, Legris S et al.. Activity of clarithromycin against M. avium infection in patients with aquired immunodeficiency syndrome.  Am Rev Respir Dis. 1991;  144 564-569
    PubMedGoogle Scholar
  • 60 Dautzenberg B, Saint Mark T, Meyohas M C et al.. Clarithromycin and other antimicrobial agents in the treatment of disseminated M. avium infections in patients with aquired immunodeficiency syndrome.  Arch Intern Med. 1993;  153 368-372
    CrossrefPubMedGoogle Scholar
  • 61 Chaisson R E, Benson C A, Dube M P et al.. Clarithromycin therapy for bacteremic M. avium complex disease: a randomized double-blind, dose-ranging study in patients with AIDS.  Ann Intern Med. 1994;  121 905-911
    PubMedGoogle Scholar
  • 62 Wallace R J, Brown B A, Griffith D E et al.. Initial clarithromycin monotherapy for M. avium-intracellulare complex lung disease.  Am J Respir Crit Care Med. 1994;  149 1335-1341
    CrossrefPubMedGoogle Scholar
  • 63 Dautzenberg B, Piperno D, Diot P et al.. Clarithromycin in the treatment of M. avium lung infections in patients without AIDS.  Chest. 1995;  107 1035-1040
    PubMedGoogle Scholar
  • 64 Pierce M, Crampton S, Henry D et al.. A randomized trial of clarithromycin as profilaxis against disseminated M. avium complex infection in patients with advanced aquired immunodeficiency syndrome.  N Engl J Med. 1996;  355 384-391
    PubMedGoogle Scholar
  • 65 Oldfield E C, Fessel W J, Dunne M W et al.. Once weekly azithromycin therapy for prevention of M. avium infection in patients with AIDS: a randomized, double-blind, placebo-controlled multi-center trial.  Clin Infect Dis. 1998;  26 611-619
    CrossrefPubMedGoogle Scholar
  • 66 Cohn D L, Fisher E J, Peng G T et al.. A prospective randomized trial of four three-drug regimens in the treatment of disseminated M. avium complex disease in AIDS patients: excess mortality associated with high dose clarithromycin. Terry Beirn Community Programs for clinical research on AIDS.  Clin Infect Dis. 1999;  29 125-133
    PubMedGoogle Scholar
  • 67 Gordin F M, Sullam P M, Shafran S D et al.. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with M. avium complex.  Clin Infect Dis. 1999;  28 1080-1085
    CrossrefPubMedGoogle Scholar
  • 68 Benson C A, Williams P L, Currier J C et al.. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for treatment of disseminated M. avium complex disease in persons with aquired immunodeficiency syndrome.  Clin Infect Dis. 2003;  37 1234-1243
    CrossrefPubMedGoogle Scholar
  • 69 Chaison R E, Keiser P, Pierce M et al.. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic M. avium complex disease in patients with HIV infection.  AIDS. 1997;  11 311-317
    CrossrefPubMedGoogle Scholar
  • 70 Ward T T, Rimland D, Kauffman C, Huycke M, Evans T G, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for M. avium complex bacteremia in patients with human immunodeficiency virus infection.  Clin Infect Dis. 1998;  27 1278-1285
    PubMedGoogle Scholar
  • 71 Wallace R J, Brown B A, Griffith D E et al.. Clarithromycin regimens for pulmonary M. avium complex.  Am J Respir Crit Care Med. 1996;  153 1766-1772
    CrossrefPubMedGoogle Scholar
  • 72 Griffith D E, Brown B A, Girard W M et al.. Azithromycin activity against M. avium complex lung disease in patients who were not infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  23 983-989
    PubMedGoogle Scholar
  • 73 Dunne M, Fessel J, Kumar P et al.. A randomized, double-blind trial comparing azithromycyn and clarithromycin in the treatment of disseminated M. avium infection in patients with human immunodeficiency virus.  Clin Infect Dis. 2000;  31 1245-1252
    CrossrefPubMedGoogle Scholar
  • 74 Iseman M D. Medical management of pulmonary disease caused by M, avium complex. In: Catanzaro A, Daley CL Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia; WB Saunders 2003: 633-641 Clinics in Chest Medicine, Vol 23
    Google Scholar
  • 75 Heifets L B, Iseman M D. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility.  N Engl J Med. 1990;  323 419
    PubMedGoogle Scholar
  • 76 Heifets L B, Iseman M D. Individualized therapy vs standard regimens in the therapy of M. avium infections [editorial].  Am Rev Respir Dis. 1991;  144 1-2
    PubMedGoogle Scholar
  • 77 Heifets L B. Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton; CRC 1991
    Google Scholar
  • 78 Heifets L. Susceptibility testing of M. avium complex isolates (review).  Antimicrob Agents Chemother. 1996;  40 1759-1767
    PubMedGoogle Scholar
  • 79 Heifets L B. Clarithromycin against M. avium complex infections (review).  Tubercle and Lung Disease. 1996;  77 19-26
    CrossrefPubMedGoogle Scholar
  • 80 Siddiqi S H, Heifets L B, Cynamon M H et al.. Rapid broth macridilution method for determination of MICs for M. avium isolates.  J Clin Microbiol. 1993;  31 2332-2338
    PubMedGoogle Scholar
  • 81 Heifets L, Mor N, Vandercolk J. M. avium strains resistant to clarithromycin and azithromycin.  Antimicrob Agents Chemother. 1993;  37 2364-2370
    PubMedGoogle Scholar
  • 82 Craft J C, Notario G F, Grosset J H, Heifets L B. Clarithromycin resistance and susceptibility pattern in M. avium strains isolated during prophylaxis of disseminated infection in patients with AIDS.  Clin Infect Dis. 1998;  2 430-434
    PubMedGoogle Scholar
  • 83 Davidson P, Khanijo V, Goble M et al.. Treatment of disease due to M. intraacellulare .  Rev Infect Dis. 1981;  3 1052-1059
    PubMedGoogle Scholar
  • 84 Horsburgh C R, Mason U G, Heifets L B et al.. Response to therapy of pulmonary M. avium-intracellulare infection correlates with results of in vitro susceptibility testing.  Am Rev Respir Dis. 1987;  135 418-421
    PubMedGoogle Scholar
  • 85 Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by M. avium complex.  Am Rev Respir Dis. 1988;  137 144-148
    PubMedGoogle Scholar
  • 86 Research Committee of the British Thoracic Society . First randomized trial on treatments for pulmonary disease caused by M. avium-intracellulare, M. malmoense, and M. xenopi in HIV-negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.  Thorax. 2001;  56 167-172
    CrossrefPubMedGoogle Scholar
  • 87 Woods G L, Brown-Elliott B A, Desmond P E et al.. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard. NCLLS document M-24-A. Wayne, PA; National Committee for Clinical Laboratory Standards 2003
    Google Scholar
  • 88 Wallace R J, Brown-Elliot B A, Ward S C et al.. Activities of linezolid against rapidly growing mycobacteria.  Antimicrob Agents Chemother. 2001;  45 764-767
    CrossrefPubMedGoogle Scholar
  • 89 Wallace R J, Brown-Elliott B A, Crist C J, Mann L, Wilson R W. Comparison of the in vitro activity of the glycyicycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycicline against isolates of nontuberculous mycobacteria.  Antimicrob Agents Chemother. 2002;  46 3164-3167
    CrossrefPubMedGoogle Scholar
  • 90 Hadjiliadis D, Adlakha A, Prakash U B. Rapidly growing mycobacterial lung infection in association with esophageal disorders.  Mayo Clin Proc. 1999;  74 744-745
    PubMedGoogle Scholar
  • 91 Ebert D L, Oliver K N. Nontuberculous mycobacteria in cystic fibrosis.  Infect Dis Clin North Am. 2002;  16 221-234
    CrossrefPubMedGoogle Scholar

Leonid HeifetsM.D. Ph.D. Sc.D. 

National Jewish Medical and Research Center

1400 Jackson St., Denver, CO 80206

Email: HeifetsL@njc.org

      >